Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19

Drug selection

Clinical trial registries such as clinicaltrials.gov and covid-nma.com were screened alongside current published literature to identify promising repurposed drug candidates. Only those approved by the USA FDA, the WHO, or the UK NICE or at least given emergency use authorisation or recommended for off label use were included in the final analysis. The Panjiva database [19] and national drug price sources were searched for available export data (Appendix 1). Remdesivir was not re-analysed in this paper as it was assessed in our previous publication [2].

Oral medications

Methodologies for estimating minimum costs of oral medication production were previously published [2]. Costs of Indian API exports were analysed (JW and JL) and independently reviewed (LE) using the online tracking database Panjiva, which showed API shipment details including quantities and costs per kilogram. All available API data from 2016 to June 2021 were included. For all oral drugs we excluded shipments <1kg in volume and excluded the 15% highest and lowest priced shipments were removed to exclude outliers. For oral drugs, 5% API loss during tableting process, and a conversion cost of $0.01 per tablet was factored into calculations, alongside a multiplier based on API mass to account for the expense of excipients (additional substances needed to convert API into the finished pharmaceutical product). Profit margins of 10% and Indian taxation of 27% on profit were added. Indian production was assumed given the country’s leading role in global generic medicine manufacturing [20].

IV dexamethasone

For injectables, an adjusted published methodology was followed to account for the cost of ampules, additional transport costs, and projected 20% API loss during formulation and filling [2,21].

Inhaled budesonide

In the STOIC and PRINCIPLE studies, patients were asked to use two puffs of a 400mcg inhaler twice daily, (800mcg BD) for 14 or 28 days, with median duration being seven days [22, 23]. Cost per kilogram of budesonide dry powder API was estimated using the same methodology above, before accounting for the cost of inhaler devices (Pulmicort turbohaler $3), additional transport costs, and a projected 20% API loss during formulation and filling. The following alternative inhalers are also permitted for use by NICE; Pulmicort Turbohaler 200 micrograms, Budelin Novolizer 200 micrograms, Easyhaler Budesonide 400 micrograms and Easyhaler Budesonide 200 micrograms.

Tocilizumab, sarilumab, baricitinib

No data for the cost or volume of monoclonal antibodies production were available, as this depends heavily on the efficiency and size of bioreactors used [24]. Also, no API data was available for baricitinib or casirivimab and imdevimab. Therefore, list prices in a range of countries, in particular developing economies, were tracked as a proxy, as it is assumed that the generic medicine could be reasonably produced at this level or less. Unfortunately, no national price data was yet available for casirivimab and imdevimab. There are news reports of tocilizumab and sarilumab being sold in Indian black markets at around $658.50 per 600mg dose [25].

International list price comparison

Estimated minimum production costs were compared with published list prices in a range of countries across the economic development spectrum to give a representative sample of prices globally. Data sources by country are detailed in Appendix 2. Data was collected and reviewed independently by JL and LE, intended to offer a snapshot at time of writing.

For consistency, a single data source per country was used for all searches of drug prices, based on the organisation of data and perceived reliability except for the USA. For the United States, we used the commercial pharmacy (USA, Pharm) cost as well as public costs from the veterans’ affairs system (USA, Vets) listed separately. This is because the USA has a healthcare system with a wide range of insurance options, and the USA veterans’ affairs programme insures many millions of Americans, whilst millions more Americans are uninsured and must pay out of pocket for most medications. Not all drugs analysed were available in every country, and in some countries without official databases, online pharmacy sites were used instead. Where several prices were available in the same database, the lowest reliable price was selected.

API availability

Panjiva data was used to analyse API export volumes per drug from India and estimate the maximum number of treatment courses potentially producible over a 12-month period.

Key assumptions

For some drugs, such as dexamethasone and tocilizumab, which are dosed on a per kilogram basis we used an average adult body mass of 70kg.

The costs of regulatory filings and approvals are often significant add-ons to the initial use of drugs in any specific country. All drugs analysed in this study have been approved for treatment for some indications already. We have not included the cost or timing associated with regulatory approvals for the use of these drugs. We assume that the WHO and other influential regulatory agencies will cooperate to define a pathway for use of these drugs which does not include additional financial outlays or filing for marketing approvals.

Dexamethasone

The widely used corticosteroid, dexamethasone has an economy of scale which supports low-cost production. Current national guidelines for dexamethasone treatment in COVID-19 most commonly recommend a 7-10-day courses of 6mg oral or IV [26, 27]. Shorter courses are used if patients improve or are discharged early, and sometimes longer courses and higher doses are used in patients with ongoing fibrosis and hyper-inflammation confirmed by high-resolution CT imaging.

This analysis used a 10-day, 6mg/day course. The weighted-mean API cost between 2016-2020 was estimated to be $1116/kg; after factoring in the costs of excipients, formulation, tax, and profit, a 10-day IV course could be reasonably producible for around $2.58 and around $0.19 as tablets (Figs.1a,1b). The higher cost of injectables reflect the potential for greater loss during production, cost of vials and increased cost of transport. Furthermore, significant non-drug costs associated with IV administration, including staff time, expendables required such as sterile water/syringes for reconstitution, and saline/IV lines for infusion were not included.

Comparatively, current list prices for oral dexamethasone were found to range from around $30.79 and $20.69 per course in UK and Israel respectively, to only $0.26 and $0.22 in China and Peru. For IV dexamethasone, course costs ranged between $26.47 (UK) and $0.98 (Vietnam) (Figs.2a, 2b). Sufficient API export shipments were identified in the most recent 12-month period to form 7.4 million courses, a substantial decrease on the four-year average between 2016-2019 at a theoretical 34.5 million 10-day courses per annum.

Tocilizumab and sarilumab

Dosages for both monoclonal antibodies are based on current UK guidelines [28]. Both are given as single dose IV infusions: sarilumab at 400mg, and tocilizumab at 8mg/kg (800mg maximum). In rare circumstances, a second tocilizumab dose can be given 12-24 hours later, depending on response to first dose. This analysis is based a single infusion of sarilumab 400mg, and tocilizumab 600mg which are guideline dose-banding suggestions for bodyweights 66kg-80kg inclusive.

International list prices per single dose of sarilumab ranged between $4850.90 (USA) to $875.70 (France); whilst for tocilizumab, single dose costs ranged between $3,625.14 (USA) to $410.59 (Australia) (Figs.2c, 2d).

Baricitinib

Baricitinib is an anti-rheumatic drug, which in clinical trials for COVID-19 [11] is dosed at 4mg/day for 14 days orally. No API data is currently available. International list prices for a 14-day treatment course were found to range between $2,326 (USA) to $6.67 (Bangladesh) (Fig.2e).

Budesonide

The STOIC study used a protocol of 800mcg BD up to 28 days, with a median duration of seven days [22,23]. Clinically, patients generally receive individual inhaler devices containing 60-200 doses of 400mcg/dose, 200mcg/dose, or 100mcg/dose which is more than sufficient for the proposed treatment duration.

Therefore, production cost of dry power budesonide inhalers containing 20mg of API was estimated to be $4.34 (100 doses of 200mcg puffs) or $4.48 if containing 40mg of API (100 doses of 400mcg puffs), based on a weighted-mean API cost of $4325/kg. This was after accounting for the cost of the inhaler device ($3), a 20% potential API loss during production, transport costs, profit, and tax (Fig.1c). International list prices vary by country depending on the availability of the 200mcg/dose or 400mcg/dose inhaler devices and are shown in Fig.2f.

API export from India in the most recent 12-month period was estimated to be sufficient for 80 million inhalers, whilst the five-year average was estimated to be around 88 million inhaler equivalents, should the entire API production volume be used for inhalers.

Limitations

This study presumed Indian generic production [20] with lower associated costs and no capital investment in new, dedicated facilities; however, following supply chain disruptions as seen earlier on in the pandemic, and currently with vaccines, countries may accept additional upfront costs and overheads for greater supply security in establishing domestic production. Fluctuating exchange rates and confidential in-country negotiated discounts for public healthcare providers means the prices we report are subject to change and are a snapshot of publicly available information at the time of writing [36]. The re-purposed drugs landscape is also a rapidly evolving pipeline, and many of the drugs we initially analysed were subsequently shown to be ineffective. Drug prices can evolve quite erratically as supply and demand, media hype and drug approval processes exert significant pressure on pharmaceutical markets and supply chains.

API production costs are subject to changes in supply and demand and optimisation of manufacturing processes. Further, analysis was dependent on Indian custom records from Panjiva. Data in other countries were unavailable so the real volume of global API production may be higher. Finally, regulatory approval costs were not considered, assuming that regulatory agencies such as WHO and FDA would coordinate rapid, emergency deployment of drugs without significant burden [37-39].

Our estimates do not include research and development costs. However, most of the investment for drug repurposing in COVID-19 has originated from public or philanthropic sources, with significant amounts of research funded directly by governments, universities, public institutions, and non-governmental organisations. A recent estimate suggested that governments have spent almost $100 billion in the last year solely on vaccine research [40].

Aspects for further research

As more information becomes available, it is possible that other promising drugs such as imatinib, infliximab or molnupiravir may be approved by the WHO if initial clinical results from pre-prints are confirmed in larger peer reviewed RCTs. A recently published study (October 2021) has found that the 5-day course of the anti-viral molnupirivir taken at 800mg BD could profitably be sold for less than $20 per person when calculated using Panjiva API export data [41] and using raw ingredients and a synthetic process with solvent capture this could drop to below $5 per course [42]. When we ran a preliminary analysis of API Panjiva data of molnupiravir in June 2021, we found a treatment course would cost more than x10 fold higher. This illustrates just how quickly small molecule nucleoside analogues can drop in price when production is upscaled. It is imperative that new and repurposed drugs are made available at fair, near-cost of production prices, to improve access and availability for all. When data is available for casirivimab and imdevimab, we would plan to analyse their prices.

There are good global accessibility and availability for steroids and budesonide. High prices of JAK inhibitors and monoclonal antibodies are barriers for patient access in healthcare systems requiring out-of-pocket co-payments or LMIC settings. The entry of biosimilars can lead to significant price reductions, even if not on the scale of chemical medications [43,44]. One reason for higher biosimilar costs could be the overly cumbersome regulatory pathway [45] that many have argued for reform. If greater emphasis is placed on encouraging biosimilar entry, prices for tocilizumab and sarilumab could be much lower and allow for greater availability.

Historically, combination therapy proved most effective against HIV/AIDS, hepatitis-C and TB - a similar approach might be needed for COVID-19 [46]. Combinations such as antivirals given concurrently with anti-inflammatory drugs or at different disease stages may prove more effective than monotherapy and warrants further investigation. Occasionally, generic combination therapies can cost less than the sum of their parts due to increased efficiency in formulation, tableting and packaging.